Outcomes Research Is Alternative To Focus On Cost, AstraZeneca Exec Says
Executive Summary
The pharmaceutical industry must be actively involved in determining health care outcomes or risk having the focus remain solely on drug costs, AstraZeneca Strategic Planning & Business Development Director Kim Slocum said during the World Health Care Congress Jan. 27 in Washington, D.C